Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This review discusses prevention, diagnosis, and treatment strategies for traction alopecia but presents no new clinical findings; the authors emphasize early intervention to prevent permanent hair loss.

Scalp Roller therapy helped improve hair growth in patients with hard-to-treat alopecia areata.

This source examines alopecia areata, an autoimmune condition causing patchy hair loss, describing the current reliance on corticosteroid injections despite their severe side effects, and explores Ayurvedic treatments identified as Shaman and Shodhan for managing an equivalent condition called Indralupta.

In this review, platelet concentrates were found to show comparable efficacy to steroids and immunosuppressive drugs in treating oral lichen planus, with some studies reporting more benefits and others noting more severe adverse reactions with platelet treatments.

This source highlights that alopecia areata is a complex autoimmune disorder leading to patchy, nonscarring hair loss with variable treatment responses, reflecting unmet clinical needs. Advances in genetic research are improving understanding, yet current treatments often lead to persistent relapses.

This review reports that pressure-induced alopecias, occurring from ischemic pressure, are often reversible without treatment if diagnosed promptly, but prognosis varies with severity and treatment timing.

This article discusses recent advancements in treatments for psoriasis, including new drug approvals and innovative therapeutic approaches, but reports no new clinical results.

In this study, microneedling and intralesional corticosteroid injections in patients with alopecia areata showed similar hair regrowth effectiveness, with microneedling resulting in more uniform but less dense regrowth and fewer side effects.

This consensus from 22 Spanish dermatologists recommends using a multimodal therapy starting with oral dutasteride, combined with topical and/or intralesional agents, and adding hydroxychloroquine if inflammation persists, to manage frontal fibrosing alopecia due to its irreversible hair loss and lack of specific approved treatments.

This study found that pediatric patients with severe alopecia areata showed significant improvement with systemic corticosteroids but typically experienced relapse within 4-5 months, also seeing an increase in weight percentiles.

This study evaluated the safety and effectiveness of HASHA, a new hyaluronic acid injectable, for chin augmentation in adults with chin retrusion. HASHA significantly improved chin appearance and satisfaction over 12 months compared to controls, with only mild or moderate transient adverse events.

This review detailed the types and mechanisms of injectable "skin boosters" and evaluated their effectiveness and safety for mitigating age-related skin changes, providing insight into their use in contemporary dermatological practice.

This study explored the effectiveness of injectable treatments for androgenetic alopecia, finding that dutasteride and growth factor formulations achieved clinically significant results compared to controls like saline and topical minoxidil, within selected trials from 2000 to 2023.

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

This case study presents a reversal of hair loss in discoid lupus erythematosus using newer treatments like injectable platelet-rich fibrin.

In this study of 35 patients with scalp alopecia areata, calcipotriol ointment led to faster and greater hair regrowth than clobetasol, though differences were not statistically significant.

This article reviews primary cicatricial alopecias, focusing on lymphocytic forms such as chronic cutaneous lupus erythematosus, according to a classification by the North American Hair Research Society, and reports no new clinical results.

This article describes the DOAJ as a comprehensive index of diverse open access journals, emphasizing its commitment to freely providing quality content online, and reports no new findings.

This article reviews common dermatologic procedures, focusing on skin biopsy techniques, with no new clinical results reported.

This review discusses the use of phosphodiesterase inhibitors for alopecia, finding promising preliminary results with topical caffeine for androgenetic alopecia and telogen effluvium, but limited success in alopecia areata.

In this double-blind study, a novel hyaluronic acid gel for lip augmentation was found to be as effective and safe as a commercially available gel, with similar adverse event profiles and high patient and investigator improvement ratings over six months.

This case report documented a 20-year-old male with alopecia areata who experienced slight hair regrowth following treatment with cyclosporine and methylprednisolone, highlighting the importance of individualized treatment plans and consideration of medication side effects.

In this case report, a 37-year-old woman with lupus panniculitis experienced successful restoration of volume in her right cheek using injectable hyaluronic acid filler after suffering from lipoatrophy.

This study observed that patient-physician alignment on alopecia areata severity largely followed Japanese Dermatological Association criteria, yet alignment on treatment satisfaction was lower, with lack of efficacy as the main dissatisfaction reason.

This overview describes the Dermatologic Surgery journal's full coverage of skin surgery topics, including various surgical procedures, but it reports no new research findings.

This study found that corticosteroids were the most common treatments for alopecia areata in the USA, but the substantial disease burden suggests a need for more effective options.

This review discusses diagnostic challenges and management approaches for pediatric hair disorders, emphasizing the importance of distinguishing between acquired and congenital conditions, and reports no clinical results.

The document explains various skin conditions in cats and how to diagnose and treat them.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.